Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Phase 2 Completed 21 enrolled CASI pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacokinetics, of Panzem® NCD in patients with metastatic, docetaxel refractory, androgen-independent prostate cancer.

Timeline

Start: 2006-11
Primary completion: 2008-11
Completion: 2008-11

Publications

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec;29(6):1465-74. doi: 10.1007/s10637-010-9455-x. Epub 2010 May 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	2-methoxyestradiol	Small molecule	1500 mg	Oral

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications